Patent ID: 11912757
Assignee: HUMABS BIOMED SA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G  Y | IPC A  C  G

Claim 18:
19. A method of inhibiting a Zika virus infection in a subject, the method comprising administering to the subject an antibody, or an antigen binding fragment thereof, that specifically binds to a Zika virus EDIII epitope,
wherein the antibody or antigen binding fragment thereof comprises the heavy chain variable region (VH) amino acid sequence of SEQ ID NO.: 26 and the light chain variable region (VL) amino acid sequence of SEQ ID NO.: 27,
and wherein the antibody or antigen binding fragment thereof comprises a Fc moiety that comprises a CH2 L4A mutation, a CH2 L5A mutation, or both.